Asset profile
TQH2929
Monoclonal antibody
Evidence outlook · lead readout
NCT07314060 · Generalized Pustular Psoriasis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07314060: This trial was randomized, quadruple-blind, and placebo-controlled, and it used a recognized disease-activity measure as its primary endpoint, which is a sound design for testing benefit in an acute flare. However, results have not been posted yet, so no outcome can be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.